Q1 2017 EPS Estimates for Corium International Inc. Cut by FBR & Co (CORI)
Corium International Inc. (NASDAQ:CORI) – Investment analysts at FBR & Co reduced their Q1 2017 earnings estimates for Corium International in a note issued to investors on Tuesday. FBR & Co analyst E. White now forecasts that the brokerage will post earnings of ($0.39) per share for the quarter, down from their prior forecast of ($0.31). FBR & Co has a “Buy” rating and a $18.00 price objective on the stock. FBR & Co also issued estimates for Corium International’s Q2 2017 earnings at ($0.44) EPS, Q3 2017 earnings at ($0.46) EPS, Q4 2017 earnings at ($0.54) EPS and FY2017 earnings at ($1.83) EPS.
A number of other research firms have also recently weighed in on CORI. Zacks Investment Research cut shares of Corium International from a “hold” rating to a “sell” rating in a research report on Tuesday, October 11th. Leerink Swann set a $16.00 price objective on shares of Corium International and gave the company a “buy” rating in a research report on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price objective on shares of Corium International in a research report on Monday, September 26th. Finally, Jefferies Group set a $9.00 price objective on shares of Corium International and gave the company a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. Corium International has a consensus rating of “Buy” and a consensus target price of $12.25.
Corium International (NASDAQ:CORI) opened at 5.51 on Thursday. Corium International has a 52-week low of $3.14 and a 52-week high of $9.93. The firm’s 50-day moving average price is $5.02 and its 200 day moving average price is $4.72. The firm’s market cap is $122.36 million.
Several institutional investors have recently modified their holdings of the company. RTW Investments LLC boosted its position in shares of Corium International by 22.6% in the third quarter. RTW Investments LLC now owns 1,045,747 shares of the biopharmaceutical company’s stock valued at $5,888,000 after buying an additional 192,786 shares during the last quarter. Opaleye Management Inc. boosted its position in shares of Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock valued at $1,390,000 after buying an additional 5,000 shares during the last quarter. Finally, Paloma Partners Management Co bought a new position in shares of Corium International during the second quarter valued at approximately $152,000. 88.35% of the stock is currently owned by institutional investors and hedge funds.
About Corium International
Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.
Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.